Epidemiology

Viral Hepatitis

Volumn , Issue , 2007, Pages 181-192

  Lavanchy, Daniel ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Epidemiology; Hepatitis B virus; Impact of vaccination; Liver disease; Person to person spread

Indexed keywords

EID: 67449091347     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470987131.ch11     Document Type: Chapter

References (168)

1. WHO. World Health Organization. Hepatitis B. World Health Organization Fact Sheet 204 (Revised October 2000). WHO Web site. 2000.
2. World Health Organization: The World Health Report. Geneva:WHO, 1997.
3. Margolis HS, Alter MJ, Hadler SC. Viral Hepatitis. In: Evans A, Kaslow R, eds. Viral Infections of Humans. New York: Plenum, 1997:363-418.
4. Brechot C, Jaffredo F, Lagorce D et al. Impact of HBV, HCV and GBV-C/HGV on hepatocellular carcinomas in Europe: results of a European concerted action. J Hepatol 1998;29:173-83.
5. Yu MC, Yuan JM, Govindarajan S, Ross RK. Epidemiology of hepatocellular carcinoma. Can J Gastroenterol 2000;14:703-9.
6. Blakely TA, Bates MN, Baker MG, Tobias M. Hepatitis B carriage explains the excess rate of hepatocellular carcinoma for Maori, Pacific Island and Asian people compared to Europeans in New Zealand. Int J Epidemiol 1999;28:204-10.
7. Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988;61:1942-56.
8. Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis 1999;19:271-85.
9. Anon. Hepatitis Viruses. Lyon, France: IARC, 1994.
10. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94:153-6.
11. Lemon SM, Layden TJ, Seeff L et al. The 20th United States-Japan Joint Hepatitis Panel Meeting. Hepatology 2000;31:800-6.
12. Lok AS. Chronic hepatitis B. N Engl J Med 2002;346:1682-3.
13. Mahoney FJ. Update on diagnosis, management, and prevention of hepatitis B virus infection. Clin Microbiol Rev 1999;12:351-66.
14. Lee WM. Hepatitis B virus infection. N Engl J Med 1997;337:1733-45.
15. Gay N, Edmunds W, Bah E, Nelson C. Estimating the Global Burden of Hepatitis B. Geneva: WHO, 2001.
16. Kubo S, Nishiguchi S, Hirohashi K et al. High prevalence of infection with hepatitis B and C viruses in patients with hepatocellular carcinoma in Japan. Hepatogastroenterology 1999;46:357-9.
17. Tsai JF, Jeng JE, Ho MS et al. Effect of hepatitis C and B virus infection on risk of hepatocellular carcinoma: a prospective study. Br J Cancer 1997;76:968-74.
18. Geller SA. Hepatitis B and hepatitis C. Clin Liver Dis 2002;6:317-34, v.
19. Chung RT, Kim AY, Polsky B. HIV/Hepatitis B and C co-infection:pathogenic interactions, natural history and therapy. Antivir Chem Chemother 2001;12(Suppl. 1)):73-91.
20. Wong JB, Koff RS, Tine F, Pauker SG. Cost-effectiveness of interferon- alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1995;122:664-75.
21. Brooks EA, Lacey LF, Payne SL, Miller DW. Economic evaluation of lamivudine compared with interferon-alpha in the treatment of chronic hepatitis B in the United States. Am J Manag Care 2001;7:677-82.
22. Rosenberg D, Cook S, Eaton S, Saunders W, Lanza L. The epidemiology, treatment patterns and resource utilization of hepatitis B patients in a large insured New England population. Pharmcoepidmiol Drug Saf 1998;7(Suppl. 2)):S132.
23. Metcalf M, Brown N, Peterson S et al. Health care costs associated with chronic hepatitis B. Am J Health Syst Pharm 1999;56:232-6.
24. Harbarth S, Szucs T, Berger K, Jilg W. The economic burden of hepatitis B in Germany. Eur J Epidemiol 2000;16:173-7.
25. Yang BM, Paik SW, Hahn OS, Yi DH, Choi MS, Payne S. Economic evaluation of the societal costs of hepatitis B in South Korea. J Gastroenterol Hepatol 2001;16:301-8.
26. WHO. Introduction of hepatitis B vaccine into childhood immunization services. Geneva; 2001. Report No.: unpublished document WHO/V&B/01.31 available on request from Department of Vaccines and Biologicals, World Health Organization, 1211 Geneva 27, Switzerland.
27. Moyer LA, Mast EE. Hepatitis B: virology, epidemiology, disease, and prevention, and an overview of viral hepatitis. Am J Prev Med 1994;10(Suppl.)):45-55.
28. Mast EE, Alter MJ. Epidemiology of viral hepatitis: an overview. Semin Virol 1993;4:273-83.
29. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000 - summary of a workshop. Gastroenterology 2001;120:1828-53.
30. FitzSimons DW, Van Damme P. Meeting Report - Prevention and control of hepatitis B in Central and Eastern Europe and the Newly Independent States, Siofok, Hungary, 6-9 October 1996. Antwerp: Viral Hepatitis Prevention Board (www.vhpb.org), 1996.
31. WHO, Global Programme for Vaccines and Immunization (GPV), (SAGE) SAGoE. Childhood diseases in Africa. 1996;GPfVaIGSAGoES.
32. Margolis HS, Alter MJ, Hadler SC. Hepatitis B: evolving epidemiology and implications for control. Semin Liver Dis 1991;11:84-92.
33. Kane M. Epidemiology of hepatitis B infection in North America. Vaccine 1995;13(Suppl. 1)):S16-S17.
34. Alter MJ. Epidemiology of hepatitis B in Europe and worldwide. J Hepatol 2003;39(Suppl. 1)):S64-S69.
35. CDC. Hepatitis B. Atlanta: CDC, 2003.
36. CDC. Vaccines to prevent hepatitis A and hepatitis B. IDU/ HIV prevention, September 2002. Atlanta: CDC, 2002 [http:// www.cdc.gov/idu/hepatitis/vaccines.pdf].
37. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-50.
38. Torres JR. Hepatitis B and hepatitis delta virus infection in South America. Gut 1996;38(Suppl. 2)):S48-S55.
39. Gust ID. Epidemiology of hepatitis B infection in the Western Pacific and South East Asia. Gut 1996;38(Suppl. 2)):S18-S23.
40. FitzSimons D, Van Damme P. Prevention and control of hepatitis B in central and eastern Europe and the newly independent states, Siofok, Hungary, 6-9 October 1996. Vaccine 1997;15:1595-7.
41. FitzSimons D, Van Damme P, Emiroglu N et al. Strengthening immunization systems and introduction of hepatitis B vaccine in central and eastern Europe and the newly independent states. Vaccine 2002;20:1475-9.
42. Viral Hepatitis Prevention Board. Prevention of Viral Hepatitis in Italy: Lessons Learnt and the Way Forward. Antwerp, Belgium:VHPB, 2002.
43. Roure C. Overview of epidemiology and disease burden of hepatitis B in the European region. Vaccine 1995;13(Suppl. 1)):S18-S21.
44. VHPB. Prevention and control of viral hepatitis in migrants and refugees. VHPB meeting. Viral Hepat 2000;8:1-7.
45. Chen CJ, Wang LY, Yu MW. Epidemiology of hepatitis B virus infection in the Asia-Pacific region. J Gastroenterol Hepatol 2000;15(Suppl.)):E3-6.
46. el-Sayed HF, Abaza SM, Mehanna S, Winch PJ. The prevalence of hepatitis B and C infections among immigrants to a newly reclaimed area endemic for Schistosoma mansoni in Sinai, Egypt. Acta Trop 1997;68:229-37.
47. Giacchino R, Zancan L, Vajro P et al. Hepatitis B virus infection in native versus immigrant or adopted children in Italy following the compulsory vaccination. Infection 2001;29:188-91.
48. Norder H, Courouce AM, Magnius LO. Molecular basis of hepatitis B virus serotype variations within the four major subtypes. J Gen Virol 1992;73(Pt 12)):3141-5.
49. Liu CJ, Kao JH, Chen PJ, Lai MY, Chen DS. Molecular epidemiology of hepatitis B viral serotypes and genotypes in Taiwan. J Biomed Sci 2002;9:166-70.
50. Sugauchi F, Orito E, Kato H et al. Genotype, serotype, and phylogenetic characterization of the complete genome sequence of hepatitis B virus isolates from Malawian chronic carriers of the virus. J Med Virol 2003;69:33-40.
51. Cui C, Shi J, Hui L et al. The dominant hepatitis B virus genotype identified in Tibet is a C/D hybrid. J Gen Virol 2002;83(Pt 11)):2773-7.
52. Liu CJ, Kao JH, Shau WY, Chen PJ, Lai MY, Chen DS. Naturally occurring hepatitis B surface gene variants in chronic hepatitis B virus infection: correlation with viral serotypes and clinical stages of liver disease. J Med Virol 2002;68:50-9.
53. Alestig E, Hannoun C, Horal P, Lindh M. Hepatitis B virus genotypes in Mongols and Australian Aborigines. Arch Virol 2001;146:2321-9.
54. Odemuyiwa SO, Mulders MN, Oyedele OI et al. Phylogenetic analysis of new hepatitis B virus isolates from Nigeria supports endemicity of genotype E in West Africa. J Med Virol 2001;65:463-9.
55. Langer BC, Frosner GG, von Brunn A. Epidemiological study of viral hepatitis types A, B, C, D and E among Inuits in West Greenland. J Viral Hepat 1997;4:339-49.
56. Ohba K, Mizokami M, Ohno T et al. Relationships between serotypes and genotypes of hepatitis B virus: genetic classification of HBV by use of surface genes. Virus Res 1995;39:25-34.
57. Arauz-Ruiz P, Norder H, Visona A, Magnius LO. Molecular epidemiology of hepatitis B virus in Central America reflected in the genetic variability of the small S gene. J Infect Dis 1997;176:851-8.
58. Norder H, Courouce AM, Magnius LO. Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes. Virology 1994;198:489-503.
59. Orito E, Mizokami M, Sakugawa H et al. A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotype B and C. Hepatology 2001;33:218-23.
60. Chu CJ, Hussain M, Lok AS. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology 2002;122:1756-62.
61. Saudy N, Sugauchi F, Tanaka Y et al. Genotypes and phylogenetic characterization of hepatitis B and delta viruses in Egypt. J Med Virol 2003;70:529-36.
62. Arauz-Ruiz P, Norder H, Visona KA, Magnius LO. Molecular epidemiology of hepatitis B virus in Central America reflected in the genetic variability of the small S gene. J Infect Dis 1997;176:851-8.
63. Kato H, Ruzibakiev R, Yuldasheva N et al. Hepatitis B virus genotypes in Uzbekistan and validity of two different systems for genotyping. J Med Virol 2002;67:477-83.
64. Sakugawa H, Nakasone H, Nakayoshi T et al. Preponderance of hepatitis B virus genotype B contributes to a better prognosis of chronic HBV infection in Okinawa, Japan. J Med Virol 2002;67:484-9.
65. Sugauchi F, Chutaputti A, Orito E et al. Hepatitis B virus genotypes and clinical manifestation among hepatitis B carriers in Thailand. J Gastroenterol Hepatol 2002;17:671-6.
66. Goldstein ST, Fiore AE. Toward the global elimination of hepatitis B virus transmission. J Pediatr 2001;139:343-5.
67. Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect Dis 2002;2:395-403.
68. Ni YH, Chang MH, Huang LM et al. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann Intern Med 2001;135:796-800.
69. Lee CL, Ko YC. Hepatitis B vaccination and hepatocellular carcinoma in Taiwan. Pediatrics 1997;99:351-3.
70. Chang MH, Chen CJ, Lai MS et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997;336:1855-9.
71. Stroffolini T, Mele A, Tosti ME et al. The impact of the hepatitis B mass immunisation campaign on the incidence and risk factors of acute hepatitis B in Italy. J Hepatol 2000;33:980-5.
72. Bonanni P, Pesavento G, Bechini A et al. Impact of universal vaccination programmes on the epidemiology of hepatitis B:10 years of experience in Italy. Vaccine 2003;21:685-91.
73. Da Villa G, Piccinino F, Scolastico C, Fusco M, Piccinino R, Sepe A. Long-term epidemiological survey of hepatitis B virus infection in a hyperendemic area (Afragola, southern Italy): results of a pilot vaccination project. Res Virol 1998;149:263-70.
74. Bonanni P, Colombai R, Gasparini R et al. Impact of routine infant and adolescent hepatitis B vaccination in Tuscany, Central Italy. Pediatr Infect Dis J 1999;18:677-82.
75. Harpaz R, McMahon BJ, Margolis HS et al. Elimination of new chronic hepatitis B virus infections: results of the Alaska immunization program. J Infect Dis 2000;181:413-18.
76. Gatcheva N, Vladimirova N, Kourtchatova A. Implementing universal vaccination programmes: Bulgaria. Vaccine 1995;13(Suppl. 1)):S82-S83.
77. Vardas E, Mathai M, Blaauw D, McAnerney J, Coppin A, Sim J. Preimmunization epidemiology of hepatitis B virus infection in South African children. J Med Virol 1999;58:111-15.
78. Tsebe KV, Burnett RJ, Hlungwani NP, Sibara MM, Venter PA, Mphahlele MJ. The first five years of universal hepatitis B vaccination in South Africa: evidence for elimination of HBsAg carriage in under 5-year-olds. Vaccine 2001;19:3919-26.
79. Alter MJ, Margolis HS. The emergence of hepatitis B as a sexually transmitted disease. Med Clin North Am 1990;74:1529-41.
80. Alter MJ. Epidemiology and prevention of hepatitis B. Semin Liver Dis 2003;23:39-46.
81. Alter HJ, Purcell RH, Gerin JL et al. Transmission of hepatitis B to chimpanzees by hepatitis B surface antigen-positive saliva and semen. Infect Immun 1977;16:928-33.
82. Bancroft WH, Snitbhan R, Scott RM et al. Transmission of hepatitis B virus to gibbons by exposure to human saliva containing hepatitis B surface antigen. J Infect Dis 1977;135:79-85.
83. Alter HJ, Seeff LB, Kaplan PM et al. Type B hepatitis: the infectivity of blood positive for e antigen and DNA polymerase after accidental needlestick exposure. N Engl J Med 1976;295:909-13.
84. Hindman SH, Gravelle CR, Murphy BL, Bradley DW, Budge WR, Maynard JE. ‘e’ antigen, Dane particles, and serum DNA polymerase activity in HBsAg carriers. Ann Intern Med 1976;85:458-60.
85. Shikata T, Karasawa T, Abe K et al. Hepatitis B e antigen and infectivity of hepatitis B virus. J Infect Dis 1977;136:571-6.
86. The Incident Investigation Teams and others. Transmission of hepatitis B to patients from four infected surgeons without hepatitis B e antigen. N Engl J Med 1997;336:178-84.
87. Blum HE, Stowring L, Figus A, Montgomery CK, Haase AT, Vyas GN. Detection of hepatitis B virus DNA in hepatocytes, bile duct epithelium, and vascular elements by in situ hybridization. Proc Natl Acad Sci USA 1983;80:6685-8.
88. Koff RS. Viral Hepatitis. Philadelphia: Lippincott-Raven, 1993.
89. Shimoda T, Shikata T, Karasawa T, Tsukagoshi S, Yoshimura M, Sakurai I. Light microscopic localization of hepatitis B virus antigens in the human pancreas. Possibility of multiplication of hepatitis B virus in the human pancreas. Gastroenterology 1981;81:998-1005.
90. Mayans MV, Hall AJ, Inskip HM et al. Do bedbugs transmit hepatitis B? Lancet 1994;343:761-3.
91. Mast EE, Alter MJ, Margolis HS. Strategies to prevent and control hepatitis B and C virus infections: a global perspective. Vaccine 1999;17:1730-3.
92. Maynard JE. Nosocomial viral hepatitis. Am J Med 1981;70:439-44.
93. Alter HJ, Holland PV, Morrow AG, Purcell RH, Feinstone SM, Moritsugu Y. Clinical and serological analysis of transfusionassociated hepatitis. Lancet 1975;2:838-41.
94. Seeff LB, Wright EC, Zimmerman HJ, McCollum RW. VA cooperative study of post-transfusion hepatitis, 1969-1974: incidence and characteristics of hepatitis and responsible risk factors. Am J Med Sci 1975;270:355-62.
95. Hutin YJ, Goldstein ST, Varma JK et al. An outbreak of hospital- acquired hepatitis B virus infection among patients receiving chronic hemodialysis. Infect Control Hosp Epidemiol 1999;20:731-5.
96. Alter MJ, Ahtone J, Maynard JE. Hepatitis B virus transmission associated with a multiple-dose vial in a hemodialysis unit. Ann Intern Med 1983;99:330-3.
97. Polish LB, Shapiro CN, Bauer F et al. Nosocomial transmission of hepatitis B virus associated with the use of a spring-loaded finger-stick device. N Engl J Med 1992;326:721-5.
98. Drescher J, Wagner D, Haverich A et al. Nosocomial hepatitis B virus infections in cardiac transplant recipients transmitted during transvenous endomyocardial biopsy. J Hosp Infect 1994;26:81-92.
99. Lettau LA, McCarthy JG, Smith MH et al. Outbreak of severe hepatitis due to delta and hepatitis B viruses in parenteral drug abusers and their contacts. N Engl J Med 1987;317:1256-62.
100. Alter MJ, Hadler SC, Margolis HS et al. The changing epidemiology of hepatitis B in the United States. Need for alternative vaccination strategies. JAMA 1990;263:1218-22.
101. Broers B, Junet C, Bourquin M, Deglon JJ, Perrin L, Hirschel B. Prevalence and incidence rate of HIV, hepatitis B and C among drug users on methadone maintenance treatment in Geneva between 1988 and 1995. AIDS 1998;12:2059-66.
102. Corona R, Caprilli F, Giglio A et al. Risk factors for hepatitis B virus infection among heterosexuals attending a sexually transmitted diseases clinic in Italy: role of genital ulcerative diseases. J Med Virol 1996;48:262-6.
103. Estrada AL. Epidemiology of HIV/AIDS, hepatitis B, hepatitis C, and tuberculosis among minority injection drug users. Public Health Rep 2002;117(Suppl. 1)):S126-S134.
104. Rickenbach M. Akute virale Hepatitiden in der Schweiz: Die Arztmeldungen der Jahre 1984 bis 1987. Soz Präventivmed 1991;36:39-45.
105. Steffen T, Gutzwiller F. Hepatitis B und C bei intravenös Drogenkonsumierenden in der Schweiz. Schweiz Rundsch Med Prax 1999;88:1937-44.
106. Mast EE, Alter MJ. Prevention of hepatitis B virus infection among healthcare workers. In: Ellis RS, ed. Hepatitis B Vaccines in Clinical Practice. New York: Marcel Dekker, 1992:295-307.
107. Roggendorf M, Viazov S. Health care workers and hepatitis B. J Hepatol 2003;39(Suppl. 1)):S89-S92.
108. Limentani AE, Elliott LM, Noah ND, Lamborn JK. An outbreak of hepatitis B from tattooing. Lancet 1979;2:86-8.
109. Kent GP, Brondum J, Keenlyside RA, LaFazia LM, Scott HD. A large outbreak of acupuncture-associated hepatitis B. Am J Epidemiol 1988;127:591-8.
110. Bond WW, Favero MS, Petersen NJ, Gravelle CR, Ebert JW, Maynard JE. Survival of hepatitis B virus after drying and storage for one week. Lancet 1981;1:550-1.
111. CDC. Lack of transmission of hepatitis B to humans after oral exposure to hepatitis B surface antigen-positive saliva. MMWR Morb Mortal Wkly Rep 1978;27:247-8.
112. Glaser JB, Nadler JP. Hepatitis B virus in a cardiopulmonary resuscitation training course. Risk of transmission from a surface antigen-positive participant. Arch Intern Med 1985;145:1653-5.
113. Toukan AU, Sharaiha ZK, Abu-el-Rub OA et al. The epidemiology of hepatitis B virus among family members in the Middle East. Am J Epidemiol 1990;132:220-32.
114. Pon EW, Ren H, Margolis H, Zhao Z, Schatz GC, Diwan A. Hepatitis B virus infection in Honolulu students. Pediatrics 1993;92:574-8.
115. Bernier RH, Sampliner R, Gerety R, Tabor E, Hamilton F, Nathanson N. Hepatitis B infection in households of chronic carriers of hepatitis B surface antigen: factors associated with prevalence of infection. Am J Epidemiol 1982;116:199-211.
116. Szmuness W, Harley EJ, Prince AM. Intrafamilial spread of asymptomatic hepatitis B. Am J Med Sci 1975;270:293-304.
117. Petersen NJ, Barrett DH, Bond WW et al. Hepatitis B surface antigen in saliva, impetiginous lesions, and the environment in two remote Alaskan villages. Appl Environ Microbiol 1976;32:572-4.
118. Gan CY, Yap SF, Ngeow YF, Wong HC. Hepatitis B infection among Chinese STD patients in Kuala Lumpur, Malaysia. Sex Transm Dis 1991;18:84-8.
119. Struve J, Giesecke J, Lindh G, Weiland O. Heterosexual contact as a major route for transmission of acute hepatitis B among adults. J Infect 1990;20:111-21.
120. Germinario C, Luigi Lopalco P, Chicanna M, Da Villa G. From hepatitis B to hepatitis A and B prevention: the Puglia (Italy) experience. Vaccine 2000;18:3326.
121. Spada E, Mele A, Ciccozzi M et al. Changing epidemiology of parenterally transmitted viral hepatitis: results from the hepatitis surveillance system in Italy. Dig Liver Dis 2001;33:778-84.
122. Mele A, Spada E, Sagliocca L et al. Risk of parenterally transmitted hepatitis following exposure to surgery or other invasive procedures: results from the hepatitis surveillance system in Italy. J Hepatol 2001;35:284-9.
123. Goldstein ST, Alter MJ, Williams IT et al. Incidence and risk factors for acute hepatitis B in the United States, 1982-1998: implications for vaccination programs. J Infect Dis 2002;185:713-19.
124. van Steenbergen JE, Niesters HG, Op de Coul EL et al. Molecular epidemiology of hepatitis B virus in Amsterdam 1992-1997. J Med Virol 2002;66:159-65.
125. Barrett CL, Austin H, Louv WC, Alexander WJ, Hadler SC. Risk factors for hepatitis B virus infection among women attending a clinic for sexually transmitted diseases. Sex Transm Dis 1992;19:14-18.
126. Stevens CE, Neurath RA, Beasley RP, Szmuness W. HBeAg and anti-HBe detection by radioimmunoassay: correlation with vertical transmission of hepatitis B virus in Taiwan. J Med Virol 1979;3:237-41.
127. Xu ZY, Liu CB, Francis DP et al. Prevention of perinatal acquisition of hepatitis B virus carriage using vaccine: preliminary report of a randomized, double-blind placebo-controlled and comparative trial. Pediatrics 1985;76:713-18.
128. Beasley RP, Hwang LY. Postnatal infectivity of hepatitis B surface antigen-carrier mothers. J Infect Dis 1983;147:185-90.
129. Franks AL, Berg CJ, Kane MA et al. Hepatitis B virus infection among children born in the United States to Southeast Asian refugees. N Engl J Med 1989;321:1301-5.
130. Hurie MB, Mast EE, Davis JP. Horizontal transmission of hepatitis B virus infection to United States-born children of Hmong refugees. Pediatrics 1992;89:269-73.
131. Van Damme P, Cramm M, Van der Auwera JC, Vranckx R, Meheus A. Horizontal transmission of hepatitis B virus. Lancet 1995;345:27-9.
132. Deinhardt F. Epidemiology and mode of transmission of viral hepatitis A and B. Am J Clin Pathol 1976;65(5 Suppl.)):890-7.
133. Marinier E, Barrois V, Larouze B et al. Lack of perinatal transmission of hepatitis B virus infection in Senegal, West Africa. J Pediatr 1985;106:843-9.
134. Hutin YJ, Harpaz R, Drobeniuc J et al. Injections given in healthcare settings as a major source of acute hepatitis B in Moldova. Int J Epidemiol 1999;28:782-6.
135. Kane A, Lloyd J, Zaffran M, Simonsen L, Kane M. Transmission of hepatitis B, hepatitis C and human immunodeficiency viruses through unsafe injections in the developing world:model-based regional estimates. Bull World Health Organ 1999;77:801-7.
136. Simonsen L, Kane A, Lloyd J, Zaffran M, Kane M. Unsafe injections in the developing world and transmission of bloodborne pathogens: a review. Bull World Health Organ 1999;77:789-800.
137. Douvin C, Simon D, Zinelabidine H, Wirquin V, Perlemuter L, Dhumeaux D. An outbreak of hepatitis B in an endocrinology unit traced to a capillary-blood-sampling device. N Engl J Med 1990;322:57-8.
138. Vickers J, Painter MJ, Heptonstall J, Yusof JH, Craske J. Hepatitis B outbreak in a drug trials unit: investigation and recommendations. Commun Dis Rep CDR Rev 1994;4:R1-5.
139. Oren I, Hershow RC, Ben-Porath E et al. A common-source outbreak of fulminant hepatitis B in a hospital. Ann Intern Med 1989;110:691-8.
140. FitzSimons DW, Van Damme P, Emiroglu N et al. Meeting Report - Strengthening immunization systems and introduction of hepatitis B vaccine in central and eastern Europe and the Newly Independent States, St. Petersburg, Russian Federation. Antwerp: Viral Hepatitis Prevention Board (www.vhpb.org), 2001.
141. Hasselhorn HM, Hofmann F. Übertragung von HBV, HCV und HIV durch infektiöses medizinisches Personal - eine Übersichtsdarstellung. Chirurg 2000;71:389-95.
142. Mahoney FJ, Stewart K, Hu H, Coleman P, Alter MJ. Progress toward the elimination of hepatitis B virus transmission among health care workers in the United States. Arch Intern Med 1997;157:2601-5.
143. Stroffolini T, Petrosillo N, Ippolito G et al. Hepatitis B vaccination coverage among healthcare workers in Italy. Infect Control Hosp Epidemiol 1998;19:789-91.
144. CDC. Perspectives in disease prevention and health promotion update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in health-care settings. MMWR Morb Mortal Wkly Rep 1988;37:377-88.
145. Bell DM, Shapiro CN, Culver DH, Martone WJ, Curran JW, Hughes JM. Risk of hepatitis B and human immunodeficiency virus transmission to a patient from an infected surgeon due to percutaneous injury during an invasive procedure: estimates based on a model. Infect Agents Dis 1992;1:263-9.
146. Bonanni P, Bonaccorsi G. Vaccination against hepatitis B in health care workers. Vaccine 2001;19:2389-94.
147. Schmunis GA, Zicker F, Cruz JR, Cuchi P. Safety of blood Suppl.y for infectious diseases in Latin American countries, 1994-1997. Am J Trop Med Hyg 2001;65:924-30.
148. Seed CR, Cheng A, Ismay SL et al. Assessing the accuracy of three viral risk models in predicting the outcome of implementing HIV and HCV NAT donor screening in Australia and the implications for future HBV NAT. Transfusion 2002;42:1365-72.
149. Tosti ME, Solinas S, Prati D et al. An estimate of the current risk of transmitting blood-borne infections through blood transfusion in Italy. Br J Haematol 2002;117:215-19.
150. Jackson BR, Busch MP, Stramer SL, AuBuchon JP. The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. Transfusion 2003;43:721-9.
151. Busek SU, Baba EH, Tavares Filho HA et al. Hepatitis C and hepatitis B virus infection in different hemodialysis units in Belo Horizonte, Minas Gerais, Brazil. Mem Inst Oswaldo Cruz 2002;97:775-8.
152. Quale JM, Landman D, Wallace B, Atwood E, Ditore V, Fruchter G. Déjà vu: nosocomial hepatitis B virus transmission and fingerstick monitoring. Am J Med 1998;105:296-301.
153. Colin JF, Cazals-Hatem D, Loriot MA et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 1999;29:1306-10.
154. Puoti M, Airoldi M, Bruno R et al. Hepatitis B virus co-infection in human immunodeficiency virus-infected subjects. AIDS Rev 2002;4:27-35.
155. Chan G, Kowdley KV. Extrahepatic manifestations of chronic viral hepatitis. Compr Ther 1995;21:200-5.
156. Shusterman N, London WT. Hepatitis B and immune-complex disease. N Engl J Med 1984;310:43-6.
157. Lieber CS, Garro A, Leo MA, Mak KM, Worner T. Alcohol and cancer. Hepatology 1986;6:1005-19.
158. Oshima A, Tsukuma H, Hiyama T, Fujimoto I, Yamano H, Tanaka M. Follow-up study of HBs Ag-positive blood donors with special reference to effect of drinking and smoking on development of liver cancer. Int J Cancer 1984;34:775-9.
159. De Bac C, Stroffolini T, Gaeta GB, Taliani G, Giusti G. Pathogenic factors in cirrhosis with and without hepatocellular carcinoma:a multicenter Italian study. Hepatology 1994;20:1225-30.
160. Dore GJ, Freeman AJ, Law M, Kaldor J. Is severe liver disease a common outcome for people with chronic hepatitis C? J Gastroenterol Hepatol 2002;17:423-30.
161. Ikeda K, Saitoh S, Koida I et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993;18:47-53.
162. Puoti M, Spinetti A, Ghezzi A et al. Mortality for liver disease in patients with HIV infection: a cohort study. J Acquir Immune Defic Syndr 2000;24:211-17.
163. Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991;350:429-31.
164. Stern MC, Umbach DM, Yu MC, London SJ, Zhang ZQ, Taylor JA. Hepatitis B, aflatoxin B(1), and p53 codon 249 mutation in hepatocellular carcinomas from Guangxi, People’s Republic of China, and a meta-analysis of existing studies. Cancer Epidemiol Biomarkers Prev 2001;10:617-25.
165. Ross RK, Yuan JM, Yu MC et al. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet 1992;339:943-6.
166. McGlynn KA, Rosvold EA, Lustbader ED et al. Susceptibility to hepatocellular carcinoma is associated with genetic variation in the enzymatic detoxification of aflatoxin B1. Proc Natl Acad Sci USA 1995;92:2384-7.
167. Henry SH, Bosch FX, Bowers JC. Aflatoxin, hepatitis and worldwide liver cancer risks. Adv Exp Med Biol 2002;504:229-33.
168. Namgyal P. Impact of hepatitis B immunization, Europe and worldwide. J Hepatol 2003;39(Suppl. 1)):S77-S82.